1	Non-invasive lung cancer diagnosis and prognosis based on multi-analyte
2	liquid biopsy
3	
4	Kezhong Chen <sup>1,#</sup> , Jianlong Sun <sup>2,#</sup> , Heng Zhao <sup>1,#</sup> , Ruijingfang Jiang <sup>2</sup> , Jianchao
5	Zheng <sup>2</sup> , Zhilong Li <sup>2</sup> , Jiaxi Peng <sup>2</sup> , Haifeng Shen <sup>1</sup> , Kai Zhang <sup>1</sup> , Jin Zhao <sup>2</sup> , Shida
6	Zhu <sup>3,4</sup> , Yuying Wang <sup>2,*</sup> , Fan Yang <sup>1,*</sup> , Jun Wang <sup>1,*</sup> .
7	
8	1. Department of Thoracic Surgery, Peking University People's Hospital, Beijing,
9	100044, China
10	2. Envelope Health Biotechnology Co. Ltd., BGI-Shenzhen, Shenzhen, 518083,
11	China
12	3. BGI Genomics, BGI-Shenzhen, Shenzhen, 518083, China
13	4. Shenzhen Engineering Laboratory for Innovative Molecular Diagnostics, BGI-
14	Shenzhen, Shenzhen, 518120, China
15	<sup>#</sup> Authors contributed equally to this work.
16	* Corresponding authors: Yuying Wang ( <u>wangyuying@bgi.com</u> ), Fan Yang
17	( <u>yangfan@pkuph.edu.cn</u> ), and Jun Wang ( <u>wangjun@pkuph.edu.cn</u> ).
18	
19	Abstract
20	Chest LDCT provides an effective approach for lung cancer screening, yet has
21	been found to generate a large number of false positives during practice due to
22	excessive diagnosis of pulmonary lesions of indeterminate clinical significance. In
23	this study, we performed comprehensive genetic and epigenetic profiling of
24	cfDNA from lung cancer patients and individuals bearing benign lung lesions,
25	using ultra-deep targeted sequencing and targeted bisulfite sequencing. We found
26	that cfDNA mutation profile alone has relatively limited power in distinguishing

27 malignant from benign plasma, while cfDNA methylation profiling showed a

better performance for classification of the two groups and combination of genetic
and epigenetic features of cfDNA along with serum protein marker further
improved the classification accuracy. We also identified novel methylation-based
prognostic markers and showed that an integrated model that combined cfDNA
mutational status and methylation-based prognostic markers improved prediction
for lung cancer survival. Our results highlight the potential of the multi-analyte
assay for non-invasive lung cancer diagnosis and prognosis.

### 35

### 36 Introduction

Lung cancer (LC), with the highest incidence and mortality rates among cancers
worldwide, is the leading cause of death in many countries including China [1].
The stage at which lung cancer is diagnosed has a significant impact on the
prognosis of this disease. A study showed that the 5-year overall survival rate was
57.4% for localized lung and bronchus cancers and merely 5.2% for distant ones
[2]. However, timely detection of lung cancer remains difficult since patients are
often asymptomatic at an early stage of the disease.

44

Low-dose computed tomography (LDCT), as a replacement of chest radiography, 45 is the most extensively recommended lung cancer screening method currently [3]. 46 47 Its effectiveness has been proved by the National Lung Screening Trial (NLST) which demonstrated a relative reduction of 20.0% in lung cancer mortality with 48 this approach [4]. However, LDCT as a screening method poses radiation risk. The 49 cumulative radiation exposure of a participant following the current lung cancer 50 screening protocols over 30 years could reach 420 mSv, which exceed those 51 52 among nuclear power workers as well as atomic bomb survivors [5]. Additionally, the false-positive rate of LDCT can be up to 50%, while the positive predictive 53 54 value could be as low as 2.4% [6]. This is due to the difficulty in distinguishing

between malignant and benign lung nodules by CT scans [7]. The resultant
overdiagnosis and overtreatment could potentially lead to adverse medical events
[8]. Therefore, new screening technologies for overcoming these drawbacks are
required.

59

Derived from tumor cells, circulating tumor DNA (ctDNA) in plasma of cancer 60 61 patients provides valuable information about cancer and also holds great promise for non-invasive early cancer detection [9-13]. However, since ctDNA is diluted by 62 63 circulating cell-free DNA (cfDNA) of noncancerous origins, its detection poses 64 significant challenges especially during early stages of cancer when the tumor mass is small [14,15]. Notably, ctDNA contains both genetic and epigenetic 65 information that may derive from the tumor, including but are not limited to 66 mutation spectrum, copy number variation (CNV), changes in genomic 67 methylation level, and fragmentation patterns [13,16-18]. Therefore, it is an 68 attractive hypothesis that simultaneous analysis of multiple features may improve 69 70 ctDNA detection. Nevertheless, previous studies on early cancer detection have mostly focused on a single feature of the ctDNA, such as cancer driver gene 71 mutations or alterations in the methylome [14,19-21]. 72

73

In this study, we have developed a set of experimental and computational tools to measure both genetic and epigenetic signals from plasma cfDNA of lung cancer (LC) patients as well as patients bearing benign lung lesions (BLN) using highthroughput sequencing, aiming to explore the potential utility of blood-based biomarkers for lung cancer diagnosis and for prediction tumor recurrence risk.

80 Methods

81 Patients enrolled and samples collected in this study

Between December 2013 and December 2018, 128 LC and 94 BLN patients were 82 enrolled in this study at the Peking University People's Hospital, Beijing, China, 83 with the informed consent form signed by every participant. This study was 84 approved by the Ethics Committee of Peking University People's Hospital 85 (No.2017PHB106-01). The histopathological classification was based on the 2015 86 World Health Organization classification [22]. 4-8 mL blood was collected from 87 88 the participants before surgery into 10 mL K2EDTA tubes (BD, 366643) and stored at room temperature. Plasma separation was performed within 4 hours after 89 collection by centrifugation at 1,600×g for 10 minutes and then at 16,000×g for 90 another 10 minutes at room temperature. Separated plasma was stored at -80 °C 91 until DNA extraction. 25 pairs of lung cancer tissues and adjacent normal tissues 92 were collected during surgery at stored at -80 °C. 93

94

### 95 DNA Extraction and Quality Control

Plasma cfDNA extraction was conducted by MagPure Circulating DNA Maxi Kit 96 97 (Magen, 12917PC-100) following the manufacturer's instructions with some modifications. The concentration of cfDNA was measured using the Qubit<sup>TM</sup> 98 dsDNA HS Assay Kit (Thermo Fisher Scientific, Q32854). The quality of cfDNA 99 was analyzed by Agilent High Sensitivity DNA Kit (Agilent Technologies, 5067-100 4626) and Agilent 2100 Bioanalyzer (Agilent Technologies). cfDNA samples with 101 excessive high molecular weight nucleic acids were considered as contaminated by 102 white blood cell genomic DNA (WBC gDNA) and were excluded from further 103 104 analysis. gDNA was extracted from WBC, lung cancer tissues, and normal tissue adjacent to the tumor (NAT) using MagPure Buffy Coat DNA Midi KF Kit 105 (Magen, D3537-02) per manufacturer's instruction, and DNA concentration was 106 measured by Qubit<sup>™</sup> dsDNA HS Assay Kit. 107

108

# 109 Capture panel design for targeted ultra-deep Next Generation Sequencing110 (NGS)

111 We used a 139-gene pan-cancer panel for targeted ultra-deep sequencing. Targeted

112 genes and exons were selected based on mutation frequency in the The Cancer

113 Genome Atlas (TCGA) database [23] and the COSMIC database of somatic

114 mutations in cancer[24], prioritizing cancer driver genes [25]), and exons with

115 TCGA or COSMIC hotspot mutations.

116

### 117 Library preparation for targeted ultra-deep NGS

To reduce noises that may derive from PCR and/or sequencing errors, we used a
duplex unique molecular identifier (UMI) strategy in library preparation, adapted
from a previous study [26]. Briefly, cfDNA was end-repaired and ligated to
sequencing adapters, and index PCR was performed followed by purification by
Agencourt AMPure XP beads (Beckman Coulter, A63882). WBC gDNA was
processed in the same way except for it was fragmented by sonication before
library preparation.

125

126 Target capture reactions were performed using xGen® Lockdown® Reagents (IDT 127 technologies) per manufacturer's instruction. Captured Libraries were amplified in a 50 µL PCR mix composed of 25 µL 2× KAPA HiFi Hot Start Ready Mix, 5 µL 128 PCR primer pair (10  $\mu$ M) and 20  $\mu$ L beads suspensions with the following cycling 129 conditions: 45s at 98°C, followed by 13 cycles of 98°C for 15 s, 60°C for 30 s, and 130 72°C for 30 s; final extension was performed at 72°C for 1min. Libraries were 131 purified by Agencourt AMPure XP beads, quantified by Qubit<sup>™</sup> dsDNA HS 132 Assay Kit, and sequenced on MGISEQ-2000 (MGI Tech) using 2×100 paired-end 133 sequencing. 134

### 135

### 136 Library preparation for targeted bisulfite sequencing

- 137 To improve the quality of cfDNA whole-genome bisulfite sequencing (WGBS)
- 138 libraries, we adopted a single-stranded DNA (ssDNA) library preparation strategy.
- 139 Briefly, bisulfite conversion was performed on input DNA using EZ DNA
- 140 Methylation-Gold<sup>™</sup> Kit (Zymo Research, D5006) per manufacturer's instructions.
- 141 Next, bisulfite-converted ssDNA was ligated to sequencing adaptors as described
- 142 previously [27]. gDNA extracted from lung cancer or normal tissues was
- 143 fragmented by sonication before library preparation.

144 Targeted capture reactions of the WGBS libraries were performed using SeqCap

145 Epi CpGiant Probes (Roche) following the manufacturer's instruction. Captured

libraries were amplified and sequenced on MGISEQ-2000 using 2×100 paired-endsequencing.

148

### 149 Variant analysis

Targeted sequencing data from cfDNA libraries were processed as follows: UMI
sequences were trimmed from fastq data using in-house scripts and were adapter

- trimmed and quality trimmed using SOAPnuke-2.0.3 [28]. Reads were aligned
- against the human reference genome (hg19) using BWA-MEM (version 0.7.17)

154 [29]. Candidate mutations were identified from the aligned reads using a two-step

155 procedure: Firstly, hotspot mutations (defined as point mutations, small insertions

- and deletions represented in COSMIC database
- 157 (https://cancer.sanger.ac.uk/cosmic, version 85) with >= 20 cancer cases) were
- 158 identified using the in-house script and filtered using an allele fraction cutoff of
- 159 0.05% (except for indels, which were not filtered). Secondly, non-hotspot
- 160 mutations were identified using freebayes (version 1.1.0) [30] and filtered using an

allele fraction cutoff of 0.05%. These two sets of variants were combined and 161 filtered for potential germline variants (with allele fraction >=25%) [14]. Variants 162 were further filtered for germline mutations using a custom germline database 163 derived from the ExAC germline variants data [31] and 1000 Genome data [32], as 164 well as a custom false-positive database. Remaining variants were then annotated 165 using VEP (version 95.2-0) [33]. For cfDNA samples, variants were further 166 filtered using the following set of criteria: variants were first filtered to exclude 167 intronic and silent mutations. For the remaining hotspot variants, only those with at 168 least 3 supporting UMI families and at least one supporting duplex UMI family 169 were retained (except for indels). For the remaining non-hotspot variants, only 170 ones with at least 8 supporting UMI families and at least one supporting duplex 171 UMI family, or ones with at least 6 supporting UMI families and at least two 172 duplex UMI families, were retained. Non-hotspot mutations with a SIFT prediction 173 of "tolerated" and a PolyPhen prediction of "benign" were excluded. Finally, 174 within the remaining non-hotspot variants, only those with a SIFT score  $\leq 0.02$ 175 176 and a PolyPhen score  $\geq 0.95$ , or a PolyPhen score of 1, or a SIFT score of 0, were retained. For WBC samples, no further filtering was applied. To derive the final set 177 of variants for plasma sample, cfDNA variants were filtered with variants 178 identified from the matched WBC sample. 179

180

### **181** Mutation scoring system

Variants were classified and weighted according to the following arbitrarily
defined tiered scoring system: COSMIC hotspots with more than 500 cancer cases
were given a score of 8; TCGA hotspot variants [34] or COSMIC hotspots with
more than 100 cancer cases and not in the former class were given a score of 4;
COSMIC hotspots with more than 20 cancer cases and not in the former class were
given a score of 2; the rest of variants were given a score of 1.

#### 188

### 189 Methylation data analysis

- 190 Targeted bisulfite sequencing data were processed as follows. First, low-quality
- reads and 3' sequencing adapters were trimmed by fastp (version 0.19.7) [35].
- 192 Then, pair-end reads were aligned to the hg19 reference genome using
- 193 BitMapperBS (version 1.0.0.8) [36]. Only reads mapped in proper pair to a unique
- 194 genomic position and spanning an insert size between 30 bp and 500 bp were
- retained. Next, duplicates were marked with sambamba (v0.6.8) [37]. Finally,
- 196 methylation rates were calculated as #C/(#C+#T) for individual CpG sites with at
- 197 least 4x coverage using MethylDackel (https://github.com/dpryan79/MethylDackel,
- 198 version 0.3.0).
- 199

### 200 Identification of differentially methylated regions (DMRs)

A Bayesian hierarchical model was used to detect the differential methylated loci 201 between 25 lung cancer tissues and 25 matched normal tissues (p<0.001 and 202 203 delta>0.2) [38]. To account for the spatial correlation of methylation ratio, smoothing was applied to combine the information from proximal CpG sites to 204 identify differentially methylated regions (DMRs). DMRs were defined as the 205 regions satisfying the following criteria:  $\geq$ 50bp, containing  $\geq$ 3 CpG sites within the 206 region, and  $\geq 80\%$  CpG sites with significant p-values. Only hypermethylated 207 DMRs were used in the subsequent analysis. 208

209

### 210 **Predictive model construction**

211 Regional methylation ratio was calculated per DMR for each cfDNA sample

sequenced by targeted bisulfite sequencing and processed as features by dividing

- the sum of methylated cytosine by the sum of depth in the DMR. Ten-fold cross-
- validation was performed to validate random forest models for classifying plasma

cfDNA of lung cancer patients from that of patients bearing benign lung nodulesusing the python package scikit-learn [39].

217

Feature selections were performed on the training data only, using a feature importance cutoff of 0.008. Random forest models were fitted using the selected DMRs with the parameters: number of trees=60, depth=5. The fitted models were then applied in the validation set from which the sensitivity, specificity, and area under the curve (AUC) were calculated. Multi-omics prediction models were trained and validated similarly, except that feature selections were applied to the DMR features only.

225

### 226 Identification and validation of prognostic markers

To identify methylation-based prognostic markers, samples were randomly divided 227 into a training set and testing set using a 60/40 split. We applied the following 228 procedure to select the potential methylation-related prognostic factors and to fit 229 230 prognosis model in the training set: we first removed DMRs with a standard deviation<0.03 from the identified lung cancer DMRs as mentioned above since 231 less variant features provided limited information; we then used the selected DMRs 232 to fit a LASSO Cox proportional hazard model on OS. Through 10-fold cross-233 validation, we chose the tuning parameter  $\lambda$  when the partial likelihood deviance 234 reached the lowest, from which DMRs were further filtered and the coefficients of 235 the each DMR were obtained. We calculated the methylation-based prognostic 236 237 score (MPS) for each individual as the sum of the products of the DMR methylation level and its coefficient and combined the mutation score (wSUMAF) 238 with the MPS as the multi-omics score. We then assessed the association of lung 239 cancer prognosis with mutation score and multi-omics score separately in the 240 241 training set and testing set. Kaplan–Meier curves were plotted for each analysis.

Finally, two separate multivariate Cox proportional hazard models were built on 242 wSUMAF only and both wSUMAF and MPS with adjustment of age, stage, 243 histological type and smoking status in the testing set. To avoid information loss 244 through categorization, both wSUMAF and MPS were analyzed as continuous 245 variables in the multivariate Cox regression. To compare the performance of two 246 models, the incident cases / dynamic controls ROC curve was plotted [40]. The R 247 248 package of glmnet, survival, survminer (https://CRAN.Rproject.org/package=survminer), risksetROC were used. The analyses procedure is 249

summarized in the Supplementary Figure 19.

251

## 252 **Results**

### 253 Study design and patients

In this study, we performed a comprehensive analysis of sequence alterations and 254 methylation pattern of plasma cfDNA as well as levels of serum protein markers 255 from lung cancer patients and patients bearing benign lung nodules, in order to 256 explore the possibility of using these features to non-invasively distinguish 257 between malignant and benign lung nodules (Figure 1A). Blood samples were 258 collected from 128 lung cancer (LC) and 94 benign lung nodule (BLN) patients 259 (Table 1). As expected, LC patients had significantly higher mean plasma cfDNA 260 level  $(20.53 \pm 1.04 \text{ ng/ml})$  than BLN patients  $(13.78 \pm 1.14 \text{ ng/ml}, \text{p}=2.14\text{E}-05,$ 261 student's t-test) (Supplementary Figure 1), in accordance with the previous report 262 [41]. 263

264

# Targeted ultra-deep NGS detected distinct mutational spectrum of plasma cfDNA and WBC gDNA

267 To profile sequence alterations carried by cfDNA, we performed targeted ultra-

deep NGS on plasma cfDNA extracted from 111 LC patients and 78 BLN patients

(Supplementary Table 1) using a panel covering exons of 139 cancer driver genes 269 270 selected based on TCGA and COSMIC databases (Supplementary Table 2, see Methods for panel design). We achieved an average raw target sequencing depth 271 over 50,000× and an average deduped sequencing depth over  $5,000\times$ 272 (Supplementary Figure 2). We designed a set of stringent thresholds to identify the 273 most reliable variants, based on the number of supporting UMI families and duplex 274 275 UMI families, the allele fractions, and function predictions (see Methods for details). Potential germline variants were also removed before downstream 276 277 analysis. To test the limit of detection (LOD) and evaluate the accuracy of our method, we first performed spike-in experiments using a reference standard 278 containing 8 single-nucleotide variants (SNVs) and cfDNA from two healthy 279 individuals by the method previously reported [42]. Results indicated that our 280 targeted ultra-deep NGS method could efficiently detect mutations with variant 281 allele frequencies (VAFs) of 0.1% and 0.25%, with a sensitivity of 91.7% (22/24) 282 and 95.5% (21/22) respectively (Figure 1B and Supplementary Figure 3). The 283 284 VAFs of identified sequence alterations using this method ranged from 0.03% to 6.82% with a median of 0.16% for LC patients and from 0.05% to 2.00% with a 285 median of 0.22% for BLN patients (Figure 1C). In total, 193 and 46 mutations 286 were detected in 75 (out of 111, 68%) LC patients and 33 (out of 78, 42%) BLN 287 plasma cfDNA, respectively (Supplementary Figure 4 and 5). As expected, cfDNA 288 of LC patients appears to harbor more sequence alterations than that of BLN 289 patients (Supplementary Figure 6). 290

291

292 Recent studies suggest that some of the variants found in cfDNA may derive from

the process of clonal hematopoiesis and confound the analysis [43]. To address this,

294 genomic DNA (gDNA) of white blood cell (WBC) from cfDNA mutation-positive

295 participants were also sequenced with ultra-deep targeted sequencing (see

Methods). Non-synonymous variants were detected in WBC of 73 (out of 75, 97%) 296 297 LC patients and 33 (out of 33, 100%) BLN patients respectively (Supplementary Figure 7 and 8). The AFs of variants observed in WBC samples were mostly less 298 than 1%, ranging from 0.04% to 7.10% (Figure 1D). Within these WBC-shared 299 cfDNA variants, the most frequently mutated genes included TP53, CBL, APOB 300 and CSMD3 for LC plasma, and CBL, CSMD3, and STAT3 for BLN plasma 301 302 (Supplementary Figure 9). Of these, TP53 and CBL are regarded as canonical CH 303 genes (other canonical CH genes such as DNMT3A, TET2 and ASXL1 were not 304 included our targeted panel) [43]. Moreover, AFs of variants shared by plasma cfDNA and matched WBC samples are highly correlated (Figure 1E), suggesting 305 that these mutations indeed originated from WBC and should be removed for 306 downstream analysis. Notably, a number of these mutations were hotspot 307 mutations of cancer driver genes (defined as variants with >=20 reported cases in 308 the COSMIC database (Supplementary Figure 10). The percentages of cfDNA 309 variants matching corresponding WBC sample were 20.7% (40 out of 193) for LC 310 311 cfDNA and 39.1% (18 out of 46) for BLN cfDNA, suggesting that a significant 312 portion of cfDNA variants derive from clonal hematopoiesis, especially in BLN 313 plasma (p=8.89E-03, chi-squared test).

314

After filtering for variants potentially derived from clonal hematopoiesis, 153 315 variants remained in 67 (out of 111, 60.36%) cfDNA samples from LC patients 316 317 (Figure 2B and Supplementary Table 3), with AFs ranging from 0.03% to 6.00% 318 (median was 0.13%, Figure 2A-C and Supplementary Figure 11). The most frequent variants were missense mutations (n=102, 67%), followed by nonsense 319 320 mutations (n=33, 22%). SNVs (n=137, 90%) were predominantly C>T transitions (n=95, 69%) (Figure 2C), which was a feature discovered recently in East Asian 321 322 LC patients [44]. Mutation frequency analysis revealed that TP53 was the most

commonly mutated gene in LC plasma (mutated in 23% of LC cfDNA samples), 323 324 consistent with TCGA findings [45-47]. Other frequently mutated genes included EGFR (8%), PTPN11 (8%), APC (7%), APOB (7%), KMT2C (5%), and KMT2D 325 (5%) (Figure 2A and Supplementary Figure 12), hence identifying a spectrum 326 mostly consistent with previous reports of lung cancer mutation spectrum 327 (Supplementary Figure 13) [45,48-53]. As for LC subtypes, cfDNA samples from 328 LUSC patients were more frequently muated than that from LUAD patients 329 (Supplementary Figure 13 and Supplementary Table 4). 330

331

After stringent QC filtering as well as filtering for WBC-matched variants, as 332 many as 28 mutations remained in 23 (out of 78) BLN plasma cfDNA samples 333 (Figure 2D and Supplementary Table 5), although the percentage of positive 334 samples was much less compared to LC plasma (29.49% vs. 60.36%, p=2.87E-05, 335 chi-squared test). These mutations had AFs ranging from 0.05% to 1.91% (Figure 336 2A). The median AF (0.13%) was the same as that of LC plasma cfDNA, yet the 337 338 highest AF was much less (1.91% vs. 6.00%). The most frequently mutated genes in BLN plasma were KRAS (5%), CSMD3 (4%), APC (3%), ATM (3%), KMT2D 339 (3%), and TP53 (3%) (Figure 2D). Notably, 39.3% (11 out of 28) of these were 340 COSMIC hotspot mutations (such as variants affecting the KRAS G12 residue) 341 (Supplementary Table 5). These results suggest that BLN cfDNA harbored 342 common cancer driver mutations, a phenomenon consistent with previous and 343 recent reports that cancer driver mutations are prevalent among normal tissues 344 [43,54,55]. The mutation spectrum of BLN plasma cfDNA is notably different 345 from that of LC plasma: the most frequent mutations found in BLN plasma cfDNA 346 347 were KRAS (5%) and CSMD3 (4%). EGFR variants were never detected in BLN plasma. *KRAS* variants, however, had almost identical frequency in both groups. 348

*TP53* mutations were also observed in BLN plasma cfDNA albeit at a much lowerfrequency (3%).

351

A predictive model based on somatic mutations to distinguish LC from BLN 352 Next, we asked whether it would be possible to differentiate LC and BLN plasma 353 based on their different cfDNA mutation signatures and AF distribution. To 354 355 quantify the cfDNA mutational burden, we constructed a mutation score for each cfDNA sample as either a simple summation of the allele fractions of all variants 356 identified therein (SUMAF) or a weighted sum of the allele fractions based on a set 357 of pre-defined weights (weighted SUMAF, or wSUMAF), weighing more on 358 TCGA hotspot cancer driver mutations and COSMIC hotspot mutations, and less 359 on other variants (see Methods for details). We found both scoring methods 360 produced modest classification accuracy for distinguishing LC from BLN plasma: 361 the wSUMAF model generated an area under curve (AUC) value of 0.68, with a 362 sensitivity of 59.5% and a specificity of 71.8% (Figure 2E and Supplementary 363 Figure 14) and the SUMAF model had a similar performance. 364

365

366 Classification of LC and BLN plasma based on cfDNA methylation data

367 To identify lung cancer-specific epigenetic changes, such as abnormalities in 5-mC

methylome, we performed whole-genome bisulfite sequencing (WGBS) on 25

pairs of LC tissue and normal tissue adjacent to the tumor (NAT) among which 21

pairs were from LUAD, 3 from LUSC and 1 from LCSC (Figure 3A). 315

371 differentially methylated regions (DMRs) were identified using a cutoff of delta  $\beta$ 

value greater than 0.2 and p-value less than 0.001 (see Methods), including 293

373 hyper DMRs and 22 hypo DMRs (Figure 3B). There were a lot more hyper DMRs

than hypo DMRs, consistent with the belief that genomic regulatory regions such

as promoters of potential tumor suppressor genes undergo remarkable

hypermethylation in tumorigenesis. Gene ontology (GO) annotations revealed that
the 293 hyper DMRs were significantly enriched for genes encoding DNA-binding
domains and homeobox domains, as well as genes involved in the developmental
and transcriptional regulation process (Figure 3C), consistent with the possibility
that these genes may be involved in lung cancer development by regulating cell
differentiation, and when silenced by promoter methylation, may cause cell
transformation.

383

Unsupervised hierarchical clustering using the regional methylation ratio of the identified DMRs perfectly separated LC tissues and NAT with the exception of a single LC sample, highlighting the pronounced epigenetic dysregulation of lung cancer cells. We did not observe notable differences between cancer stages (Figure 388 3B), consistent with the notion that epigenomic change is an early driver of oncogenesis that persists through later stages of cancer progression.

390

391 We next performed comprehensive analysis of 5-mC methylation profile of plasma 392 cfDNA for 111 LC patients and 87 BLN patients using targeted bisulfite sequencing, covering 5.6 million CpG sites located within gene regions, as well as 393 CpG islands, shelves, and shores (Supplementary Table 1). Based on the hyper 394 DMRs we defined using tissue WGBS, we were able to build random forest 395 models that classify LC from BLN plasma (see Methods). To estimate 396 397 classification accuracy, we performed 10-fold cross-validation (CV), for which AUC was 0.75 (Supplementary Figure 15), a performance slightly better than the 398 mutation-based model. In order to determine whether we could effectively 399 400 distinguish lung cancer plasma from healthy plasma using fewer DMR markers, we also performed further feature selection. We found that by selecting DMRs 401 402 with feature importance > 0.008 in each random forest model for each CV, we

- 403 could achieve a CV AUC of 0.72 (Figure 3D). A total of 76 DMRs were retained
- in the final CV model. Among cancer patients, the detection sensitivity of the final
- 405 CV models was higher in LUSC patients than that in LUAD samples
- 406 (Supplementary Table 6).
- 407

### 408 Multi-omics analysis to differentiate LC from BLN plasma

409 Next, we attempted to integrate multi-omics features to further improve the

- 410 diagnostic power of our classification model. Indeed, on 91 LC and 71 BLN
- 411 cfDNA samples that had been sequenced with both targeted deep sequencing and
- 412 targeted bisulfite sequencing (Supplementary Table 1), we found that combination
- 413 of methylation features (based on a total of 81 DMRs selected using the same
- 414 feature selection criteria described earlier) and the SUMAF mutation score
- achieved an AUC of 0.75, generating a sensitivity of 78.0% and specificity of 60.5%
- 416 (Figure 4C), compared to an AUC of 0.68 achieved by mutation score alone
- 417 (Figure 4A), and an AUC of 0.72 achieved by methylation features alone in the
- same set of samples using the same CV procedures (Figure 4B).
- 419

420 In addition, levels of 5 serum marker, CEA, CYFRA21-1, NSE, CA19-9, and

421 CA125, were also measured in a subset of the blood samples (Supplementary

Table 1). We found that among the five protein markers, only CEA level appeared

to be significantly higher in LC patients than BLN patients (p=0.0438), producing

a modest AUC of 0.66 for classifying the two groups (Supplementary Figure 16

- and 17). Therefore, we tried to incorporate CEA into the predictive model in
- 426 addition to the DMR features and mutation score in samples with complete
- 427 measurements (74 LC and 60 BLN samples). The multi-omics predictive models
- 428 based on SUMAF mutation score, top DMRs (a total of 81 regions) and serum
- 429 CEA level achieved an AUC of 0.79, with 75.7% sensitivity and 68.3% specificity

430 (Figure 4E), which showed further improvement compared to the model without

431 CEA on this set of samples (AUC = 0.75) (Figure 4D). Similar to classification

432 models based solely on mutation or methylation, higher prediction accuracy was

433 found for LUSC patients than LUAD patients in integrated bi-omics and multi-

- 434 omics models (Supplementary Table 6).
- 435

# 436 cfDNA mutational burden and methylation level as prognostic factors for lung 437 cancer

We first tested whether mutational status (wSUMAF, <0 vs. >0) was associated 438 with lung cancer overall survival (OS) among lung cancer patients. We found that 439 440 among lung cancer patients, the high mutational burden was associated with a significantly worse OS (Figure 5A). Notably, among stage I lung cancer patients, a 441 significant association was observed between mutation score and OS 442 (Supplementary Figure 18). To further improve the performance of model 443 prediction on lung cancer prognosis, we attempted to identify potential 444 methylation-based prognostic biomarkers and incorporate these features into the 445 model (Supplementary Figure 19). We divided the LC cases into training and 446 447 testing set and applied a DMR selection procedure on the training set using the penalized COX regression, which identified 12 DMRs that were potentially 448 449 associated with lung cancer prognosis and obtained corresponding coefficients 450 (Supplementary Table 7, see Methods for details on the analysis procedure). Of these, DMRs of gene FOXG1/LINC01551, TMEM240, AKR7L, CBLN4, and 451 452 GCK/MYL7 appeared to be associated with a worse lung cancer prognosis while DMRs of PRDM11, LOC440028/SBF2-AS1, GF11, and ST3GAL1were associated 453 with a better prognosis. We then calculated a methylation-based prognostic score 454 (MPS) for each individual as the sum of the products of the DMR methylation 455 level and corresponding coefficient. We thereafter experimented with combining 456

the mutation score with the MPS as the bi-omics prognosis score and tested its 457 association with survival. Patients with a high mutational burden and a high MPS 458 were categorized as the high prognosis score group, while other patients were 459 categorized as the low prognosis score group. Compared to patients with a low 460 prognosis score, patients with a high prognosis score had a significantly worse OS 461 in the testing set (Figure 5B). Finally, to avoid information loss due to 462 463 categorization, we modeled both mutation score and MPS continuously (see Methods for details) and built two separate multivariate Cox proportional hazard 464 465 models on wSUMAF only, as well as on combined wSUMAF and MPS with adjustment of age, stage, histological type and smoking status. Higher AUCs were 466 467 obtained using the bi-omics prognosis model than the mutation only model (Supplementary Figure 20). Taken together, these results suggest that integrated 468 genomic features have the potential to be used as better prognostic markers for 469 470 lung cancer.

471

### 472 **Discussion**

473 In this study, we applied targeted ultra-deep sequencing to plasma cfDNA of LC and BLN patients. Matched WBC DNA were sequenced in parallel, which 474 revealed that non-synonymous variants were prevalent in WBC DNA for both the 475 476 LC and BLN group. Further analyses showed that a notable portion of cfDNA variants was detected in matched WBC (20.7% for LC plasma, and 39.1% for BLN 477 478 plasma) and their VAFs were well correlated (Figure 1E), suggesting that these variants most likely derived from WBCs. VAFs of the majority of WBC-matched 479 somatic mutations detected in the cfDNA were less than 1%, hence would have 480 481 been missed if WBC DNA has not been sequenced with ultra-deep sequencing. These results corroborate recent findings that WBCs, carrying variants 482 483 accumulated through clonal hematopoiesis (CH), constitute an important source of

somatic mutations found in cfDNA [43]. Notably, some of the shared variants 484 between cfDNA and matched WBC samples were cancer hotspot mutations 485 (Supplementary Figure 10), suggesting that CH variants may indeed significantly 486 confound cfDNA analysis if not analyzed in parallel. Interestingly, TP53 variants 487 were never detected as shared variants between BLN plasma cfDNA and matched 488 BLN WBC sample (Supplementary Figure 9). This may indicate that the 489 accumulation of TP53 mutations through CH may be somehow related to the 490 cancer risk of the individual. 491

492

After removing WBC derived variants, we found that cfDNA mutations were 493 prevalent in BLN plasma cfDNA (29.5% of samples analyzed contained at least 494 one variant). This finding is consistent with recent studies showed that benign 495 tumors may also harbor somatic mutations, including those in cancer driver genes 496 [56,57]. However, because we did not obtain matched BLN tissue for these plasma 497 498 samples, it remained to be determined whether the mutations found in BLN cfDNA could be attributed to mutations that may have arisen in the benign lesions of the 499 lung. If this indeed is the case, then we would expect it to be challenging to 500 classify malignant and benign disease solely based on cfDNA mutational status. 501 Further study would be needed to clarify whether patients bearing benign lung 502 lesions indeed have a higher mutational burden in their cfDNA than healthy 503 individuals. 504

505

Not surprisingly, predictive models built on mutation score alone had limited
classification ability for distinguishing between LC and BLN plasma (AUC = 0.68).
Some earlier studies suggested that mutational status can be used to diagnose LC
from benign lung nodules with high specificity and modest sensitivity [58,59], but

these conclusions may have suffered from potential bias caused by limited sample
sizes used in the study. Our results were obtained from a larger sample size (128
LC and 94 BLN plasma) and showed that diagnostic model based on mutational
status alone had sub-optimal classification accuracy and hints that a multi-analyte
approach is more likely to improve the detection of cancer signal.

By performing WGBS on lung cancer tissues and NATs, we identified more than 515 300 lung cancer-specific DMRs, with the majority of them being hypermethylated 516 DMRs, suggesting that hypermethylation of genome regulatory regions is an 517 518 important event in lung cancer development. Indeed, these DMRs are enriched for genes involved in transcriptional regulation and are likely to cause profound 519 520 downstream changes in gene expression and contribute to cell transformation; these genes are likely to be potential tumor suppressor genes, and many of which 521 haven't been implicated as such previously (such as SEC31B, ZNF274, and 522 523 *NXPH1*). A small number of DMRs are hypomethylated, and therefore may encode potential cancer driver genes. To our knowledge, this is the first time many of 524 these genes are implicated in epigenetic dysregulation of lung cancer. DAVID 525 functional GO analysis of biological processes revealed that these DMR genes 526 were enriched in skeletal system/embryonic organ development/morphogenesis 527 528 (Supplementary Figure 21), indicating that the lung cancer cells may have obtained some characteristics of embryonic stem cells. Functions of these genes remain to 529 be elucidated in further studies and may help us better understand the underlying 530 molecular mechanisms of lung cancer development and progression. 531

Our cfDNA methylation-based classification model for LC and BLN plasma
achieved a slightly better cross-validation AUC (0.72) than the mutation-based
model, suggesting that LC-specific methylation changes are potentially useful
markers for diagnosing lung cancers versus benign lesions. Further multi-center

studies with larger sample sizes will be needed to validate the utility of selected 536 markers and the robustness of our diagnostic model. We also noted that 537 performance of our models are slightly inferior to an earlier study which used a 538 panel of 9 methylation markers for differentiating early-stage lung cancers from 539 benign pulmonary nodules (AUC of 0.82 (0.70-0.93) in the test set), even though 540 we used more methylation markers in our model. The difference in model 541 542 performance could be attributed to the different study populations and cfDNA analysis methods. The smaller cohort size in the previous study may have also 543 caused over-fitting and/or over-estimation of the model performance. The 544 discrepancy also suggests that we need to be cautious with the development and 545 validation of such cfDNA-based diagnostic models, considering the intrinsic 546 technical difficulties of detecting a minute amount of cancer-derived signals in 547 circulation and relying on machine-learning approaches to build diagnostic model, 548 a process that can be heavily affected by batch effect as well as variations in 549 sample characteristics, especially with single-center clinical study. 550

In our results, we found that a higher percentage of LUSC cfDNA samples were mutation positive than LUAD samples (Supplementary Table 4). We also observed higher sensitivity for detecting LUSCs than LUADs using methylation as well as multi-omics based classification models (Supplementary Table 6). These results are consistent with the notion that LUSCs are significantly more necrotic than LUADs and are more likely to shed ctDNA into circulation [60].

Previous studies have shown that detection of cancer driver mutations in cfDNA,
when combined with serum protein markers, can be used to increase sensitivity
without significantly sacrificing specificity for cancer detection [9,61]. In our study,
the multi-omics model integrating mutation, methylation and serum protein marker
further improved the performance of the classification model (AUC of 0.79),

compared to the mutation-based model or methylation-based model. To our
knowledge, this is the first proof-of-concept study to demonstrate that genetic,
epigenetic, and proteomic analytes could be combined to increase the performance
of liquid biopsy-based diagnostic model for lung cancer. Further study with a
larger size of clinical samples will be needed to validate the robustness of this
approach.

568

We also investigated the association of prognosis of lung cancer patients with 569 570 cfDNA mutation and methylation status. Lung cancer patients with any mutation were observed to have an unfavorable outcome compared with those without, in 571 572 line with previous studies [62-64]. We also identified a group of potential methylation-based lung cancer prognostic markers from the pool of lung cancer 573 tissue-specific DMRs and constructed a methylation-based prognostic score (MPS). 574 575 Previously, multiple methylation-based prognostic classifiers had been reported for lung cancer, however, the reported markers were mostly inconsistent [25,65-67]. 576 The inconsistency could be explained by limited sample sizes, variations in study 577 design, as well as different detection methods used. Further studies will be needed 578 to validate the clinical utility of these markers including ones discovered in the 579 580 current study. Finally, we found that combining continuous MPS with the mutation score could improve the prognostication model compared with the multivariate 581 model based solely on mutation. One potential caveat to be noted here is that since 582 the estimated coefficients of DMR markers for generating the MPS might not be 583 accurate enough due to relatively limited sample size; therefore, additional study 584 with larger sample size would be necessary to validate current findings. Overall, 585 we provided proof-of-principle evidence that combination of multiple blood-586 derived biomarkers has the potential to improve lung cancer prognostication. 587

### 588

# 589 Availability of Data

- 590 The data reported in this study are alsoavailable in the CNGB Nucleotide Sequence
- 591 Archive (CNSA: https://db.cngb.org/cnsa; accession number CNP 0001236).
- 592

## 593 Acknowledgements

- 594 This study was supported by the National Natural Science Foundation of China
- 595 (No.81602001), Peking University People's Hospital Research and Development
- 596 Funds (RS2019-01), and Shenzhen Engineering Laboratory for Innovative
- 597 Molecular Diagnostics (DRC-SZ[2016]884).
- 598

### 599 **References:**

- 1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global
- 601 cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
- 602 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 68*(6), 394-424.
- 2. Howlader N, N. A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A,
- Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). (April 2019). SEER Cancer Statistics Review, 1975-2016. Retrieved from <u>https://seer.cancer.gov/csr/1975\_2016/</u>
- 3. Henschke Ci Fau Yankelevitz, D. F., Yankelevitz Df Fau Libby, D. M., Libby Dm Fau -
- 607 Pasmantier, M. W., Pasmantier Mw Fau Smith, J. P., Smith Jp Fau Miettinen, O. S., &
- Miettinen, O. S. (2006). Survival of patients with stage I lung cancer detected on CT screening.
   *The New England journal of medicine*(355), 1763-1771.
- 4. National Lung Screening Trial Research, T., Aberle, D. R., Adams, A. M., Berg, C. D., Black,
- W. C., Clapp, J. D., . . . Sicks, J. D. (2011). Reduced lung-cancer mortality with low-dose
- 612 computed tomographic screening. *The New England journal of medicine, 365*(5), 395-409.
- 5. McCunney, R. J., & Li, J. (2014). Radiation Risks in Lung Cancer Screening Programs.
- 614 CHEST, 145(3), 618-624.
- 615 6. Pinsky, P. F. (2014). Assessing the benefits and harms of low-dose computed tomography 616 screening for lung cancer. *Lung cancer management*, *3*(6), 491-498.
- 617 7. Li, Q., Li, F., Shiraishi, J., Katsuragawa, S., Sone, S., & Doi, K. (2003). Investigation of new
- 618 psychophysical measures for evaluation of similar images on thoracic computed tomography for 619 distinction between benign and malignant nodules. *Medical Physics*, *30*(10), 2584-2593.
- 8. Qian, F., Yang, W., Chen, Q., Zhang, X., & Han, B. J. J. o. T. D. (2018). Screening for early
- stage lung cancer and its correlation with lung nodule detection. *2018*, S846-S859.
- 622 9. Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., . . . Papadopoulos, N.
- 623 (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. 624 *Science*, *359*(6378), 926-930.
- 10. Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017). Circulating tumour
- 626 DNA (ctDNA) as a liquid biopsy for melanoma. *Cancer Letters, 404*, 62-69.

- 627 11. Ye, Q., Ling, S., Zheng, S., & Xu, X. (2019). Liquid biopsy in hepatocellular carcinoma:
- 628 circulating tumor cells and circulating tumor DNA. *Molecular Cancer, 18*(1), 114.
- 629 12. Lim, S. Y., Lee, J. H., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018). Liquid
- 630 biomarkers in melanoma: detection and discovery. *Molecular Cancer, 17*(1), 8.
- 13. Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M. D., & Yousef, G. M. (2017). Liquid biopsy: a
- 632 step forward towards precision medicine in urologic malignancies. *Molecular Cancer, 16*(1), 80.
- 14. Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J., . . . Velculescu, V. E.
- 634 (2017). Direct detection of early-stage cancers using circulating tumor DNA. *Science* 635 *Translational Medicine*, *9*(403), eaan2415.
- 15. Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B., Veeriah,
- 637 S., . . . Rosenthal, R. (2017). Tracking the Evolution of Non-Small-Cell Lung Cancer. *New* 638 *England Journal of Medicine*.
- 16. Otandault, A., Anker, P., Al Amir Dache, Z., Guillaumon, V., Meddeb, R., Pastor, B., . . .
- 640 Thierry, A. R. (2019). Recent advances in circulating nucleic acids in oncology. *Annals of* 641 *Oncology*.
- 642 17. Mouliere, F., & Rosenfeld, N. (2015). Circulating tumor-derived DNA is shorter than somatic 643 DNA in plasma. *Proceedings of the National Academy of Sciences*, *112*(11), 3178.
- 644 18. Murtaza, M., & Caldas, C. (2016). Nucleosome mapping in plasma DNA predicts cancer 645 gene expression. *Nature Genetics* 48, 1105
- 645 gene expression. *Nature Genetics, 48*, 1105.
- 646 19. Liu, X., Liu, L., Ji, Y., Li, C., Wei, T., Yang, X., . . . Wang, X. (2019). Enrichment of short
- 647 mutant cell-free DNA fragments enhanced detection of pancreatic cancer. *EBioMedicine*, *41*,
  648 345-356.
- 649 20. Shen, S. Y., Singhania, R., Fehringer, G., Chakravarthy, A., Roehrl, M. H. A., Chadwick,
- D., . . . De Carvalho, D. D. (2018). Sensitive tumour detection and classification using plasma
   cell-free DNA methylomes. *Nature*, *563*(7732), 579-583.
- 652 21. Xu, R.-h., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., . . . Zhang, K. (2017).
- 653 Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular 654 carcinoma. *Nature Materials, 16*, 1155.
- 22. Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015). Introduction
  to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus,
  and Heart. *Journal of Thoracic Oncology*, *10*(9), 1240-1242.
- 658 23. Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., . . . Ding, L. (2013).
- 659 Mutational landscape and significance across 12 major cancer types. *Nature, 50*2(7471), 333-660 339.
- 661 24. Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., . . . Forbes, S. A.
- (2018). COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Research*,
   47(D1), D941-D947.
- 25. Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe,
- A., . . . Ding, L. (2018). Comprehensive Characterization of Cancer Driver Genes and Mutations.
   *Cell*, *173*(2), 371-385.e318.
- 667 26. Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., . . .
- 668 Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating 669 tumor DNA. *Nat Biotechnol, 34*(5), 547-555.
- 670 27. Gansauge, M.-T., Gerber, T., Glocke, I., Korlevic, P., Lippik, L., Nagel, S., . . . Meyer, M.
- 671 (2017). Single-stranded DNA library preparation from highly degraded DNA using T4 DNA 672 ligase. *Nucleic acids research*, *45*(10), e79-e79.
- 673 28. Chen, Y., Chen, Y., Shi, C., Huang, Z., Zhang, Y., Li, S., . . . Chen, Q. (2017). SOAPnuke: a
- 674 MapReduce acceleration-supported software for integrated quality control and preprocessing of 675 high-throughput sequencing data. *GigaScience*, 7(1).
- 676 29. Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with Burrows–Wheeler
- 677 transform. *Bioinformatics*, *25*(14), 1754-1760.

- 678 30. Garrison, E., & Marth, G. (2012). Haplotype-based variant detection from short-read
- 679 sequencing. arXiv, 1207.
- 680 31. McVean, G. A., Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti,
- 681 A.,... University of, G. (2012). An integrated map of genetic variation from 1,092 human
- 682 genomes. Nature, 491(7422), 56-65.
- 32. Siva, N. (2008). 1000 Genomes project. Nature Biotechnology, 26(3), 256-256. 683
- 684 33. McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., . . .
- 685 Cunningham, F. (2016). The Ensembl Variant Effect Predictor. Genome Biology, 17(1), 122.
- 686 34. Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe,
- 687 A., . . . Ding, L. (2018). Comprehensive Characterization of Cancer Driver Genes and Mutations. 688 Cell, 173(2), 371-385.e318.
- 689 35. Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ 690 preprocessor. Bioinformatics, 34(17), i884-i890.
- 691 36. Cheng, H., & Xu, Y. (2018). BitMapperBS: a fast and accurate read aligner for whole-692 genome bisulfite sequencing. *bioRxiv*, 442798.
- 693 37. Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J., & Prins, P. (2015). Sambamba: fast
- 694 processing of NGS alignment formats. *Bioinformatics*, 31(12), 2032-2034.
- 695 38. Wu, H., Xu, T., Feng, H., Chen, L., Li, B., Yao, B., . . . Conneely, K. N. (2015). Detection of
- 696 differentially methylated regions from whole-genome bisulfite sequencing data without replicates. 697 Nucleic Acids Research, 43(21), e141-e141.
- 39. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., . . . Dubourg, 698
- 699 V. J. J. o. m. l. r. (2011). Scikit-learn: Machine learning in Python. 12(Oct), 2825-2830.
- 700 40. Heagerty, P. J., & Zheng, Y. J. B. (2005). Survival model predictive accuracy and ROC 701 curves. 61(1), 92-105.
- 702 41. Szpechcinski, A., Rudzinski, P., Kupis, W., Langfort, R., Orlowski, T., & Chorostowska-
- 703 Wynimko, J. (2016). Plasma cell-free DNA levels and integrity in patients with chest radiological
- 704 findings: NSCLC versus benign lung nodules. Cancer Letters, 374(2), 202-207.
- 705 42. Liu, J., Chen, X., Wang, J., Zhou, S., Wang, C. L., Ye, M. Z., . . . Qian, Z. Y. (2019).
- 706 Biological background of the genomic variations of cf-DNA in healthy individuals. Annals of Oncology, 30(3), 464-470. 707
- 708 43. Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., . . . Reis-Filho, J. S.
- 709 (2019). High-intensity sequencing reveals the sources of plasma circulating cell-free DNA 710 variants. Nature Medicine.
- 711 44. Chen, Y.-J., Roumeliotis, T. I., Chang, Y.-H., Chen, C.-T., Han, C.-L., Lin, M.-H., . . . Chen,
- 712 Y.-J. (2020). Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular 713 Signatures of Pathogenesis and Progression. Cell, 182(1), 226-244.e217.
- 714 45. Cancer Genome Atlas Research, N. (2012). Comprehensive genomic characterization of 715 squamous cell lung cancers. Nature, 489(7417), 519-525.
- 716 46. The Cancer Genome Atlas Research, N., Collisson, E. A., Campbell, J. D., Brooks, A. N.,
- 717 Berger, A. H., Lee, W., ... Tsao, M.-S. (2014). Comprehensive molecular profiling of lung 718
- adenocarcinoma. Nature, 511, 543.
- 719 47. Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., . . .
- 720 Meyerson, M. (2016). Distinct patterns of somatic genome alterations in lung adenocarcinomas 721 and squamous cell carcinomas. Nature Genetics, 48, 607.
- 722 48. Ohgaki, H., Kros, J. M., Okamoto, Y., Gaspert, A., Huang, H., & Kurrer, M. O. (2004). APC
- 723 mutations are infrequent but present in human lung cancer. Cancer Letters, 207(2), 197-203.
- 724 49. Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., . . . Neel, B. G.
- 725 (2004). Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in
- 726 Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 64(24), 8816.
- 50. Zhang, Y., Wang, D. C., Shi, L., Zhu, B., Min, Z., & Jin, J. (2017). Genome analyses identify 727
- 728 the genetic modification of lung cancer subtypes. Seminars in Cancer Biology, 42, 20-30.

- 729 51. Rao, R. C., & Dou, Y. (2015), Hijacked in cancer: the KMT2 (MLL) family of
- 730 methyltransferases. Nature Reviews Cancer, 15, 334.
- 731 52. Chen, K.-Z., Lou, F., Yang, F., Zhang, J.-B., Ye, H., Chen, W., . . . Wang, J. (2016).
- 732 Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by 733 Targeted Sequencing. Scientific Reports, 6(1), 31985.
- 734 53. Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., . . . Laird, P. W.
- 735 (2018). Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 736 Types of Cancer. Cell, 173(2), 291-304.e296.
- 54. Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., . . . Getz, G. (2019). RNA 737
- 738 sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. 739 Science, 364(6444).
- 740 55. Risques, R. A., & Kennedy, S. R. (2018). Aging and the rise of somatic cancer-associated 741 mutations in normal tissues. PLoS genetics, 14(1), e1007108-e1007108.
- 742 56. Makinen, N., Mehine, M., Tolvanen, J., Kaasinen, E., Li, Y., Lehtonen, H. J., . . . Aaltonen, L.
- 743 A. (2011). MED12, the mediator complex subunit 12 gene, is mutated at high frequency in 744 uterine leiomyomas. Science, 334(6053), 252-255.
- 745 57. Lim, W. K., Ong, C. K., Tan, J., Thike, A. A., Ng, C. C., Rajasegaran, V., . . . Teh, B. T.
- 746 (2014). Exome sequencing identifies highly recurrent MED12 somatic mutations in breast 747 fibroadenoma. Nat Genet, 46(8), 877-880.
- 748 58. Ye, M., Li, S., Huang, W., Wang, C., Liu, L., Liu, J., . . . Liang, W. (2018). Comprehensive 749 targeted super-deep next generation sequencing enhances differential diagnosis of solitary
- 750 pulmonary nodules. J Thorac Dis, 10(Suppl 7), S820-s829.
- 751 59. Peng, M., Xie, Y., Li, X., Qian, Y., Tu, X., Yao, X., . . . Tian, G. (2019). Resectable lung 752 lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted
- gene mutations in plasma cell-free DNA. Journal of Medical Genetics, 56(10), 647. 753
- 754 60. Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., . . .
- 755 The, T. c. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. 756 Nature, 545(7655), 446-451.
- 757 61. Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., . . . Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. 758
- 759 Science, 359(6378), 926.
- 760 62. Isaksson, S., George, A. M., Jonsson, M., Cirenajwis, H., Jonsson, P., Bendahl, P. O., . . .
- 761 Planck, M. (2019). Pre-operative plasma cell-free circulating tumor DNA and serum protein
- 762 tumor markers as predictors of lung adenocarcinoma recurrence. Acta Oncol. 58(8), 1079-1086.
- 763 63. Kang, J., Luo, Y., Wang, D., Men, Y., Wang, J., Che, Y.-Q., & Hui, Z. (2019). Tumor
- 764 Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Disease Markers, 2019, 3837687. 765
- 64. Corradetti, M. N., Torok, J. A., Hatch, A. J., Xanthopoulos, E. P., Lafata, K., Jacobs, C., . . . 766
- 767 Nixon, A. B. (2019). Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer. Adv Radiat Oncol, 4(4), 748-752. 768
- 769 65. Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Savols, S., . . .
- 770 Esteller, M. (2013). A prognostic DNA methylation signature for stage I non-small-cell lung
- 771 cancer. J Clin Oncol, 31(32), 4140-4147.
- 772 66. Li, Y., Gu, J., Xu, F., Zhu, Q., Ge, D., & Lu, C. (2019). Novel methylation-driven genes
- identified as prognostic indicators for lung squamous cell carcinoma. Am J Transl Res, 11(4), 773 774 1997-2012.
- 775 67. Wang, Y., Deng, H., Xin, S., Zhang, K., Shi, R., & Bao, X. (2019). Prognostic and Predictive
- 776 Value of Three DNA Methylation Signatures in Lung Adenocarcinoma. Front Genet, 10, 349.
- 777

778

		LC (N=128)		BLN (N=94)	
		Number	Percentage	Number	Percentage
Gender	Female	53	41%	48	51%
Gender	Male	75	59%	46	49%
Age	Median±SD (Range)	63.00±11.58 (30-86)		55.00±10.49 (18-79)	
	LUAD	97	76%		
Histology	LUSC	23	18%		
Histology	LCC	3	2%		
	SCLC	5	4%		
	0	2	2%		
	IA	54	42%		
<b>S4</b> 0 mg	IB	29	23%		
Stage	II	17	13%		
	III	19	15%		
	IV	7	5%		
Sm alvin a	Smokers	20	16%	23	24%
Smoking	Non-smokers	33	26%	70	74%
History -	Unknown	75	59%	1	1%

### 780

# **Table 1: Clinicopathological characteristics of the patients enrolled in this**

**study.** LUAD: lung adenocarcinoma. LUSC: lung squamous cell carcinoma. LCC:

783 large cell carcinoma. SCLC: small cell lung carcinoma.

784

### 785 Figure Legends

### 786 Figure 1: Study design and variants detected by targeted ultra-deep

787 sequencing in cfDNA and WBC gDNA. (A) Schematic view of the study design.


- 788 See Methods for additional details. (B) Spike-in experiments using Multiplex I
- cfDNA Reference Standard Set which contains 8 SNVs to test the LOD of our
- targeted ultra-deep sequencing method. The sensitivity was calculated as the
- number of detected SNVs divided by the number of total spiked-in SNVs in all the
- replicates for each condition. (C) Allele fractions (x-axis, log scale) of mutations
- detected in plasma cfDNA of BLN patients (blue) and LC patients (red). (D) AF
- (x-axis, log scale) distribution of WBC gDNA variants from BLN and LC patients.
- (E) Pearson correlation of AF in cfDNA (x-axis, log scale) and AF in WBC gDNA
- 796 (y-axis, log scale). Each point represents one variant detected in matched cfDNA
- and WBC gDNA samples from the same patient.

Figure 2: Predictive model based on variants detected in plasma cfDNA after 798 filtering with matched WBC sample for shared variants. (A) AFs (x-axis, log 799 800 scale) of cfDNA variants of LC patients (red) and BLN patients (blue). (B) Oncoplot showing the 153 mutations detected in 67 out of 111 (60.36%) LC 801 samples. 45 LC samples without any mutation detected were not shown. Each 802 column represents a sample and each row a different gene. The upper barplot 803 804 represents the frequency of mutations for each sample, and the right barplot represents the frequency of mutations for each gene. Samples are ordered by the 805 most mutated genes. (C) Summary plot of the 153 mutations detected in LC 806 samples. Upper panel from left to right: Variant classification, Variant Type, and 807 SNV Class. Lower panel from left to right: Variants per sample and Variant 808 classification summary. (D) Oncoplot of the 28 mutations detected in 23 out of 78 809 (29.49%) BLN samples. 55 BLN samples without any mutation detected were not 810 shown. (E) Predictive models to distinguish LC from BLN based on mutations 811 detected. SUMAF (green): sum of AF model. Weighted\_SUMAF (red): sum of 812 weighted AF model (see Methods). The AUC of SUMAF model is 0.67 with 55.9% 813 sensitivity and 76.9% specificity. The AUC of weighted\_SUMAF model is 0.68 814 815 with 59.5% sensitivity and 71.8% specificity.

#### Figure 3: Diagnostic model for Distinguishing LC from BLN plasma by 816


- analyzing cfDNA methylation levels. (A) Differentially methylated regions 817
- (DMRs) discovered by WGBS of LC tumor and 818
- normal tissue adjacent to the tumour (NAT). Red points: Hypermethylated DMRs 819
- in LC tissues. Blue points: hypomethylated DMRs in LC tissues. From outer to 820
- inner circle, the first circle is overview of DMRs, the second circle is the area 821
- 822 statistics of hypermethylation regions (methy.diff>0.2), and the third circle is the
- area statistics of hypomethylation regions (methy.diff<-0.2). (B) Heatmap of the 823
- DMRs with hierarchical clustering. Block color represents the methylation  $\beta$  value 824
- and black represents N.A. (C) Functional annotation of the genes associated with 825
- the 293 hypermethylated DMRs by gene ontology (GO) terms using DAVID. (D) 826
- Predictive models to distinguish LC from BLN based on cfDNA methylation level 827
- with selected features (feature importance  $\geq 0.008$ ). A total of 76 DMRs were 828
- retained in the final model. The AUC is 0.72 with 80.5% sensitivity and 57.5% 829
- specificity. 830
- Figure 4: Multiomics predictive models to distinguish LC from BLN plasma. 831
- Bi-omics samples: cfDNA samples from 91 LC and 71 BLN patients with 832
- complete mutation and methylation data. Tri-omics samples: cfDNA samples from 833
- 74 LC and 60 BLN patients with complete measurement of mutation score, 834
- 835 methylation levels of selected DMR and serum CEA levels. (A) Classification
- models built based on mutation status alone in bi-omics samples; (B) Models built 836
- based on selected DMRs alone in bi-omics samples; (C) Models built based on 837
- mutation score and selected DMR in bi-omics samples; (D) Models built based on 838
- 839 mutation score and selected DMR in tri-omics samples; (E) Models based on
- 840 combined mutation score, selected DMR, and serum CEA levels in tri-omics 841 samples.
- Figure 5: Kaplan-Meier plot on omics-based lung cancer prognostic model in 842
- 843 relation to OS. (A) Mutation scores in the whole dataset; (B) Multi-omics scores in the testing set.
- 844
- 845


# Figure 1





దిదిది

<u>ÅÅÅ</u>
































Figure 4

С

1.0

0.8


True Positive Rate 7.0 9.0

0.2

0.0

0.0

False Positive Rate



False Positive Rate

1.0

False Positive Rate

Figure 5

